Hematopoietic Recovery and Safety Following Early Romiplostim Administration After Pediatric HSCT: A Prospective...

Area of Science:

• Pediatric Hematology
• Transplantation Immunology
• Pharmacology

Background:

• Delayed platelet recovery is a common complication after pediatric hematopoietic stem cell transplantation (HSCT), increasing risks and hospital stays.
• Thrombopoietin receptor agonists (TPO-RAs) show promise for post-transplant thrombocytopenia, but early pediatric data are scarce.
• This study assessed the safety and effects of early romiplostim in children undergoing HSCT.

Purpose of the Study:

• To evaluate the safety and potential impact of early romiplostim administration on platelet and hematopoietic recovery post-pediatric HSCT.
• To assess time to platelet engraftment and other secondary hematological parameters.

Main Methods:

• A prospective, randomized pilot study in children (1-18 years) undergoing HSCT.
• Participants received standard care with or without early romiplostim (5 µg/kg) on Days +1 and +8 post-transplant.
• Primary endpoint: time to platelet engraftment (≥20 × 10⁹/L for 3 days).

Main Results:

• Thirty-two children were enrolled; median platelet engraftment time was similar between romiplostim and control groups (12 vs. 12.5 days).
• No significant differences in platelet transfusion needs or nadir counts were observed.
• Higher Day +28 platelet and neutrophil counts were noted in the romiplostim group, particularly after allogeneic HSCT.

Conclusions:

• Early romiplostim administration in pediatric HSCT is safe and well-tolerated.
• The drug did not accelerate platelet engraftment but suggested potential for enhanced sustained hematopoietic recovery.
• Larger multicenter trials are needed to confirm efficacy for supporting hematopoietic recovery.